ANAPTYSBIO, Inc. (ANAB) intrinsic value & 10-year financials
ANAPTYSBIO, Inc. (ANAB) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 34.1% a year to $234.6M, with an average return on invested capital of -170.3%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $46.61
- Market cap
- $1.3B
- Revenue (FY2025)
- $234.6M
- Revenue growth (10-yr CAGR)
- 34.1%
- ROIC (10-yr avg)
- -170.3%
- Free cash flow (FY2025)
- $19.6M
ANAB 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $234.6M | -$13.2M | -$0.46 | $19.6M | 20.4% | -42.2% |
| FY2024 | $91.3M | -$145.2M | -$5.12 | -$135.7M | -125.9% | -764.4% |
| FY2023 | $17.2M | -$163.6M | -$6.08 | -$121.6M | -958.3% | -118.8% |
| FY2022 | $10.3M | -$128.7M | -$4.57 | -$74.0M | -1119.4% | -259.5% |
| FY2021 | $63.2M | -$57.8M | -$2.11 | -$47.3M | -89.9% | -430.0% |
| FY2020 | $75.0M | -$19.9M | -$0.73 | -$14.7M | -31.8% | -12.5% |
| FY2019 | $8.0M | -$97.3M | -$3.60 | -$70.3M | -1342.9% | -45.7% |
| FY2018 | $5.0M | -$61.7M | -$2.50 | -$49.6M | -1334.4% | -16.8% |
| FY2017 | $10.0M | -$30.1M | -$1.52 | -$19.7M | -287.8% | -21.4% |
| FY2016 | $16.7M | -$4.3M | -$1.62 | -$9.1M | -18.1% | 7.9% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
ANAPTYSBIO, INC is a consistent compounder, expanding top-line revenue at 34.1% annually over the past decade.
ANAPTYSBIO, INC has historically struggled to out-earn its cost of capital, averaging just -26.4% ROIC.
ANAPTYSBIO, INC capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, ANAPTYSBIO, INC is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-15.28 per share.